Reducing uric acid as a means to prevent cardiovascular and renal disease

Expert Opinion on Therapeutic Patents

Volumn 12, Issue 2, 2002, Pages 193-199

  Watanabe, Susumu ^a   Kanellis, John ^a   Nakagawa, Takahiko ^a   Han, Lin ^a   Ohashi, Ryuji ^a   Lan, Hui ^a   Feng, Lili ^a   Johnson, Richard J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Hypertension; Uric acid; Uricase; Uricosuric

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ALLOPURINOL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; AZATHIOPRINE; BENAMID; BENZBROMARONE; BENZIODARONE; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LOSARTAN; MACROGOL; MERCAPTOPURINE; PENICILLIN G; PIOGLITAZONE; PROBENECID; RASBURICASE; ROSIGLITAZONE; SALICYLIC ACID; SIBUTRAMINE; SULFINPYRAZONE; THEOPHYLLINE; TROGLITAZONE; UNINDEXED DRUG; URATE OXIDASE; URIC ACID; URICOSURIC AGENT; URICOZYME; WARFARIN; XANTHINE OXIDASE INHIBITOR; ZOPOLRESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME REPLACEMENT; FEMALE; GASTROINTESTINAL DISEASE; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; HYPOXEMIA; INSOMNIA; KIDNEY DISEASE; KIDNEY INJURY; LIVER DISEASE; LIVER FAILURE; MALE; NEPHROLITHIASIS; NONHUMAN; RASH; RAT; REVIEW; RISK FACTOR; URIC ACID STONE; URTICARIA; VASCULAR DISEASE;

EID: 0036167075     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.12.2.193     Document Type: Review

References (64)

1. Two independent mutational events in the loss of urate oxidase during hominoid evolution
2. Uric acid and the kidney
3. Epidemiology of gout and hyperuricemia
4. Asymptomatic hyperuricemia: The case for conservative management
5. Management of asymptomatic hyperuricemia
6. Serum uric acid acid and cardiovascular mortality. The NHANES I epidemiologic follow-up study, 1971-1992
7. Serum uric acid and cardiovascular events in successfully treated hypertensive patients
8. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA Study
9. Precursors of essential hypertension: Pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries
10. Serum uric acid and hypertension: The Olivetti heart study
11. Hyperuricemia in primary and renal hypertension
12. The Kidney in Gout
13. Hypertriglyceridemia and hyperuricemia are risk factors for progression of IgA nephropathy
14. Serum uric acid and renal prognosis in IgA nephropathy
15. Is serum uric acid a risk factor for coronary heart disease?
16. Risk factors for cardiovascular disease: One down, many more to evaluate
17. Much ado about nothing, or much to do about something: The continuing controversy on the role of uric acid in cardiovascular disease
18. Elevated uric acid increases blood pressure in the rat by a novel crystal independent mechanism
19. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism
20. Hyperuricemia exacerbates chronic cyclosporine nephropathy
21. New uses of allopurinol
22. A randomized controlled trial of allopurinol in coronary bypass surgery
23. Influence of allopurinol on cardiac complications in open heart operations
24. A clinical trial of allopurinol (Zyloric) for myocardial protection
25. Allopurinol pretreatment improves postoperative recovery and reduces lipid peroxidation in patients undergoing coronary artery bypass grafting
26. Allopurinol normalizes endothelial dysfunction in Type 2 diabetics with mild hypertension
27. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease
28. Effect of long-term allopurinol administration on serial GFR in normotensive and hypertensive hyperuricemic subjects
29. The influence of allopurinol on renal function in gout
30. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout
31. Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled study
32. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts
33. Allopurinol hypersensitivity syndrome: A review
34. Drug therapy: The Management of Gout
35. Clinical evaluation of benzbromarone. A new uricosuric drug
36. Ten years experience with benzbromarone in the management of gout and hyperuricaemia
37. Fatal fulminant hepatic failure associated with benzbromarone
38. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects
39. Renal effects of angiotensin II receptor blockade in normotensive subjects
40. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles
41. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients
42. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension
43. Effect of the angiotensin II antagonist losartan in hypertensive patients with renal disease
44. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension
45. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia
46. Uricolytic activity of purified uricase in two human beings
47. Urate oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia
48. Tumor lysis syndrome, case report and review of the literature
49. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies
50. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma
51. Properties of two urate oxidases modified by covalent attachment of poly(ehtyleneglycol)
52. Hypouricaemic effect of polyethylene glycol modified urate oxidase
53. Studies on antigenicity of the polyethylene glycol (PEG) modified uricase
54. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma
55. Diabetes insipidus in uricase-deficient mice: A model for evaluating therapy with poly(ethylene glycol)-modified uricase
56. Sibutramine produces dose-related weight loss
57. Effect of sibutramine on weight maintenance after weight loss: A randomized trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance
58. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial
59. Thiazolidinediones: A comparative review of approved uses
60. Troglitazone decreases serum uric acid concentrations in Type II diabetic patients and non-patients
61. Liver enzyme monitoring in patients treated with troglitazone
62. A review of rosiglitazone in Type 2 diabetes mellitus
63. Pharmacokinetics of the aldose reductase inhibitor, zopolrestat, in humans